Joanna Moes-Sosnowska

Dr. Joanna Moes-Sosnowska

National Institute of Tuberculosis and Lung Diseases, Warsaw, Mazowieckie, Poland
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2017 in Nature Genetics
Verified
Journal Article
Open access
PDF file
CPCatherine M Phelan
Catherine M Phelan
KKKaroline B Kuchenbaecker
Karoline B Kuchenbaecker
JTJonathan P Tyrer
Jonathan P Tyrer
SKSiddhartha P. Kar
Siddhartha P. Kar
KLKate Lawrenson
Kate Lawrenson
PPPaul Pharoah
Paul Pharoah
Paul Pharoah and colleagues report the results of a large genome-wide association study of ovarian cancer. They identify new susceptibility loci for different epithelial ovarian cancer histotypes and use integrated analyses of genes and regulatory features at each locus to predict candidate susceptibility genes, including OBFC1. To identify common alleles associated with different histotypes of epithelial ovarian cancer (EOC), we pooled data from multiple genome-wide genotyping projects totaling 25,509 EOC cases and 40,941 controls. We identified nine new susceptibility loci for different EOC histotypes: six for serous EOC histotypes (3q28, 4q32.3, 8q21.11, 10q24.33, 18q11.2 and 22q12.1), two for mucinous EOC (3q22.3 and 9q31.1) and one for endometrioid EOC (5q12.3). We then performed meta-analysis on the results for high-grade serous ovarian cancer with the results from analysis of 31,448 BRCA1 and BRCA2 mutation carriers, including 3,887 mutation carriers with EOC. This identified three additional susceptibility loci at 2q13, 8q24.1 and 12q24.31. Integrated analyses of genes and regulatory biofeatures at each locus predicted candidate susceptibility genes, including OBFC1, a new candidate susceptibility gene for low-grade and borderline serous EOC.

5 September 2016 in Journal of Medical Genetics
Verified
Journal Article
Open access
PDF file
MSMelissa Southey
Melissa Southey
DGDavid E Goldgar
David E Goldgar
RWRobert Winqvist
Robert Winqvist
KPKatri Pylkäs
Katri Pylkäs
FCFergus Couch
Fergus Couch
RMRoger L Milne
Roger L Milne
Background: The rarity of mutations in PALB2, CHEK2 and ATM make it difficult to estimate precisely associated cancer risks. Population-based family studies have provided evidence that at least some of these mutations are associated with breast cancer risk as high as those associated with rare BRCA2 mutations. We aimed to estimate the relative risks associated with specific rare variants in PALB2, CHEK2 and ATM via a multicentre case-control study. Methods: We genotyped 10 rare mutations using the custom iCOGS array: PALB2 c.1592delT, c.2816T>G and c.3113G>A, CHEK2 c.349A>G, c.538C>T, c.715G>A, c.1036C>T, c.1312G>T, and c.1343T>G and ATM c.7271T>G. We assessed associations with breast cancer risk (42 671 cases and 42 164 controls), as well as prostate (22 301 cases and 22 320 controls) and ovarian (14 542 cases and 23 491 controls) cancer risk, for each variant. Results: For European women, strong evidence of association with breast cancer risk was observed for PALB2 c.1592delT OR 3.44 (95% CI 1.39 to 8.52, p=7.1×10−5), PALB2 c.3113G>A OR 4.21 (95% CI 1.84 to 9.60, p=6.9×10−8) and ATM c.7271T>G OR 11.0 (95% CI 1.42 to 85.7, p=0.0012). We also found evidence of association with breast cancer risk for three variants in CHEK2, c.349A>G OR 2.26 (95% CI 1.29 to 3.95), c.1036C>T OR 5.06 (95% CI 1.09 to 23.5) and c.538C>T OR 1.33 (95% CI 1.05 to 1.67) (p≤0.017). Evidence for prostate cancer risk was observed for CHEK2 c.1343T>G OR 3.03 (95% CI 1.53 to 6.03, p=0.0006) for African men and CHEK2 c.1312G>T OR 2.21 (95% CI 1.06 to 4.63, p=0.030) for European men. No evidence of association with ovarian cancer was found for any of these variants. Conclusions: This report adds to accumulating evidence that at least some variants in these genes are associated with an increased risk of breast cancer that is clinically important.

27 March 2013 in Nature Communications
Verified
Journal Article
Open access
PDF file
HSHui Shen
Hui Shen
BFBrooke L. Fridley
Brooke L. Fridley
HSHonglin Song
Honglin Song
KLKate Lawrenson
Kate Lawrenson
JCJulie M. Cunningham
Julie M. Cunningham
CPCeleste Leigh Pearce
Celeste Leigh Pearce
HNF1B is overexpressed in clear cell epithelial ovarian cancer, and we observed epigenetic silencing in serous epithelial ovarian cancer, leading us to hypothesize that variation in this gene differentially associates with epithelial ovarian cancer risk according to histological subtype. Here we comprehensively map variation in HNF1B with respect to epithelial ovarian cancer risk and analyse DNA methylation and expression profiles across histological subtypes. Different single-nucleotide polymorphisms associate with invasive serous (rs7405776 odds ratio (OR)=1.13, P=3.1 × 10−10) and clear cell (rs11651755 OR=0.77, P=1.6 × 10−8) epithelial ovarian cancer. Risk alleles for the serous subtype associate with higher HNF1B-promoter methylation in these tumours. Unmethylated, expressed HNF1B, primarily present in clear cell tumours, coincides with a CpG island methylator phenotype affecting numerous other promoters throughout the genome. Different variants in HNF1B associate with risk of serous and clear cell epithelial ovarian cancer; DNA methylation and expression patterns are also notably distinct between these subtypes. These findings underscore distinct mechanisms driving different epithelial ovarian cancer histological subtypes.

1 January 2013 in Polish Journal of Pathology
Verified
Journal Article
Open access
JKJolanta Kupryjańczyk
Jolanta Kupryjańczyk
ADAgnieszka Dansonka-Mieszkowska
Agnieszka Dansonka-Mieszkowska
JMJoanna Moes-Sosnowska
Joanna Moes-Sosnowska
JPJoanna Plisiecka-Hałasa
Joanna Plisiecka-Hałasa
LSLukasz Michal Szafron
Lukasz Michal Szafron
BŚBeata Śpiewankiewicz
Beata Śpiewankiewicz
Ovarian tumors from two patients, compatible by histological and immunohistochemical criteria with small cell carcinoma of hypercalcemic type (SCCHT) (WT1+, EMA dispersed+, synaptophysin+ or dispersed+), were extensively sampled in order to find clues to their histogenesis. Subsequently, small...

2 February 2010 in BMC Medical Genetics
Verified
Journal Article
Open access
PDF file
ADAgnieszka Dansonka-Mieszkowska
Agnieszka Dansonka-Mieszkowska
AKAnna Kluska
Anna Kluska
JMJoanna Moes-Sosnowska
Joanna Moes-Sosnowska
MDMichalina Dabrowska
Michalina Dabrowska
DNDorota Nowakowska
Dorota Nowakowska
JKJolanta Kupryjańczyk
Jolanta Kupryjańczyk
Background: PALB2 protein was recently identified as a partner of BRCA1 and BRCA2 which determines their proper function in DNA repair. Methods: Initially, the entire coding sequence of the PALB2 gene with exon/intron boundaries was evaluated by the PCR-SSCP and direct sequencing methods on 70 ovarian carcinomas. Sequence variants of interest were further studied on enlarged groups of ovarian carcinomas (total 339 non-consecutive ovarian carcinomas), blood samples from 334 consecutive sporadic and 648 consecutive familial breast cancer patients, and 1310 healthy controls from central Poland. Results: Ten types of sequence variants were detected, and among them four novel polymorphisms: c.2996+58T>C in intron 9; c.505C>A (p.L169I), c.618T>G (p.L206L), both in exon 4; and c.2135C>T (A712V) in exon 5 of the PALB2 gene. Another two polymorphisms, c.212-58A>C and c.2014G>C (E672Q) were always detected together, both in cancer (7.5% of patients) and control samples (4.9% of controls, p = 0.2). A novel germline truncating mutation, c.509_510delGA (p.R170fs) was found in exon 4: in 2 of 339 (0.6%) unrelated ovarian cancer patients, in 4 of 648 (0.6%) unrelated familial breast cancer patients, and in 1 of 1310 controls (0.08%, p = 0.1, p = 0.044, respectively). One ovarian cancer patient with the PALB2 mutation had also a germline nonsense mutation of the BRCA2 gene. Conclusions: The c.509_510delGA is a novel PALB2 mutation that increases the risk of familial breast cancer. Occurrence of the same PALB2 alteration in seven unrelated women suggests that c.509_510delGA (p.R170fs) is a recurrent mutation for Polish population.

19 November 2015 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
HMHuong D. Meeks
Huong D. Meeks
HSHonglin Song
Honglin Song
KMKyriaki Michailidou
Kyriaki Michailidou
MBManjeet K. Bolla
Manjeet K. Bolla
JDJoe Dennis
Joe Dennis
DGDavid E. Goldgar
David E. Goldgar
Background: The K3326X variant in BRCA2 (BRCA2*c.9976A>T; p.Lys3326*; rs11571833) has been found to be associated with small increased risks of breast cancer. However, it is not clear to what extent linkage disequilibrium with fully pathogenic mutations might account for this association. There is scant information about the effect of K3326X in other hormone-related cancers.